The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Overt testosterone deficiency is associated with a reduction in BMD and alteration in body composition. However, there are few data concerning the impact of mild hypogonadism on these parameters. PATIENTS AND METHOD: We have identified a cohort of 36 men aged < 55 years with mild Leydig cell impairment, defined by a raised LH level (LH ≥ 8 IU/l) in the presence of a testosterone level in the lower half of the normal range or frankly subnormal (< 20 nmol/l), following treatment with procarbazine‐containing chemotherapy regimens or high‐dose chemotherapy for haematological malignancy. These men underwent measurements of BMD (measured by dual‐energy X‐ray absorptiometry (DXA), single energy X‐ray absorptiometry (SXA) and quantitative CT (QCT)), body composition (DXA), markers of bone turnover, serum lipids and serum IGF‐1. To allow for changes that may be directly attributable to the underlying disease or its treatment, results were compared with those obtained in 14 men who had received the same chemotherapy for the same diseases but had normal LH and testosterone levels (controls). RESULTS: When data from all 50 men were considered together there were significant reductions in BMD of the lumbar spine both by DXA (Z = − 0.34, P = 0.01) and QCT (Z = − 1.5, P < 0.0001), at the femoral neck (Z = − 0.52, P < 0.0001) and distal forearm (Z = − 0.21, P = 0.05). Mean femoral neck BMD was significantly lower in patients compared with controls (Z = − 0.68 vs. Z = − 0.11, P = 0.05) and there was a nonsignificant trend towards lower lumbar spine BMD measured by QCT (Z = − 1.64 vs. Z = − 1.10; P = 0.09). In addition, serum testosterone level and testosterone:LH ratio significantly correlated with femoral neck BMD (r = 0.28, P = 0.05 and r = 0.37, P = 0.008, respectively). There were no significant differences in lean body mass, fat mass and percentage fat between the patients and controls. There was, however, a difference in the distribution of body fat with a propensity for the patients to accrue truncal fat, and the serum testosterone level significantly inversely correlated with percentage of truncal fat (r = − 0.29, P = 0.04). There were no significant differences in lipid levels, IGF‐1 levels or markers of bone turnover between the patients and controls. CONCLUSIONS: These data suggest that mild Leydig cell impairment may have significant effects on bone mineral density and may result in subtle body composition changes, although in men who have received cytotoxic chemotherapy, other factors also contribute to the observed osteopenia. Testosterone replacement may be beneficial in some of these men and this requires further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 3×
“An increase in total body fat, truncal fat, and alterations in the distribution of fat have previously been described in overtly hypogonadal men (Katznelson et al., 1996, 1998).”
BackgroundLong-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4163 · Cited by 559 · cited 1×
“Testosterone replacement in frankly hypogonadal males increases bone density and muscle mass, and reduces body fat (Brodsky et al., 1996; Katznelson et al., 1996; Behre et al., 1997; Bhasin et al., 1997; Leifke et al., 1998).”
BackgroundTestosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men1
Bhasin, S., Storer, T. W., Berman, N., Yarasheski, K. E., Clevenger, B., Phillips, J., Lee, W. P., Bunnell, T. J., & Casaburi, R. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3733 · Cited by 522
Brodsky, I. G., Balagopal, P., & Nair, K. S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.10.8855787 · Cited by 444 · cited 1×
“Testosterone replacement in frankly hypogonadal males increases bone density and muscle mass, and reduces body fat (Brodsky et al., 1996; Katznelson et al., 1996; Behre et al., 1997; Bhasin et al., 1997; Leifke et al., 1998).”
BackgroundEndocrine, Paracrine and Autocrine Regulation of Testicular Steroidogenesis
Huhtaniemi, I., & Toppari, J. (1995) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4899-0952-7_3 · Cited by 82 · cited 1×
“This may be mediated either through structural changes resulting from a decrease in testicular volume, a reduction in testicular blood ¯ow (Wang et al., 1983) or alterations in the paracrine control of Leydig cell function (Huhtaniemi & Toppari, 1995; Carreau, 1996).”
Background
Cited by
Pedersen, M., Bruunsgaard, H., Weis, N., Hendel, H. W., Andreassen, B. U., Eldrup, E., Dela, F., & Pedersen, B. K. (2003) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(03)00027-7 · Cited by 342
Late Side Effects and Quality of Life After Radiotherapy for Rectal Cancer
Bruheim, K., Guren, M. G., Skovlund, E., Hjermstad, M. J., Dahl, O., Frykholm, G., Carlsen, E., & Tveit, K. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.03.010 · Cited by 278
Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review
Gebauer, J., Higham, C., Langer, T., Denzer, C., & Brabant, G. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00092 · Cited by 161
Golds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration?
Scheele, C., Nielsen, A. R., Walden, T. B., Sewell, D. A., Fischer, C. P., Brogan, R. J., Petrovic, N., Larsson, O., Tesch, P. A., Wennmalm, K., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8520com · Cited by 110
Metadata
- Authors
- Howell, S. J., Radford, J. A., Adams, J. E., & Shalet, S. M.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2000-05-19
- Volume
- 52
- Issue
- 5
- Pages
- 609-616
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2054988105
- Cited by
- 50
- References
- 5
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.